Canandaigua National Trust Co of Florida Buys New Position in Pfizer Inc. $PFE

Key Points

• Canandaigua National Trust Co. of Florida initiated a Pfizer position of 42,478 shares valued at approximately $1.21 million in the third quarter. Institutional investors and hedge funds collectively own 68.36% of Pfizer.
• Pfizer’s stock recently traded at $27.96, while analysts maintain a consensus “Hold” rating and an average price target of $28.56. The company reported quarterly earnings and revenue above expectations and raised its full-year 2026 guidance to $2.80–$3.00 in earnings per share.
• Pfizer declared a quarterly dividend of $0.43 per share, equivalent to a $1.72 annualized payout and a yield of about 6.2%. However, its payout ratio above 226% raises concerns about long-term dividend sustainability.

Canandaigua National Trust Co of Florida purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 42,478 shares of the biopharmaceutical company's stock, valued at approximately $1,211,000.

Several other hedge funds have also recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its stake in shares of Pfizer by 15.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company's stock worth $132,365,000 after acquiring an additional 745,213 shares during the period. Handelsbanken Fonder AB increased its stake in shares of Pfizer by 10.4% during the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company's stock worth $59,295,000 after acquiring an additional 232,528 shares during the period. Leuthold Group LLC purchased a new position in Pfizer during the second quarter worth about $4,887,000. Park National Corp OH raised its holdings in Pfizer by 332.1% during the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company's stock worth $5,829,000 after purchasing an additional 186,053 shares in the last quarter. Finally, 111 Capital acquired a new stake in Pfizer in the second quarter valued at about $3,706,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock traded up $0.46 during mid-day trading on Wednesday, reaching $27.96. The company had a trading volume of 31,210,171 shares, compared to its average volume of 40,538,586. Pfizer Inc. has a 1 year low of $23.62 and a 1 year high of $29.21. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company has a market capitalization of $159.39 billion, a P/E ratio of 36.80, a P/E/G ratio of 1.84 and a beta of 0.32. The stock's 50-day simple moving average is $27.50 and its 200-day simple moving average is $26.48.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the firm posted $0.78 EPS. The company's revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 6.2%. Pfizer's dividend payout ratio is 226.32%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA (tucatinib) regimen with trastuzumab and pertuzumab as a front-line maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. Expanding TUKYSA into an earlier treatment setting could increase its addressable market and support oncology revenue growth. Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
• Positive Sentiment: Pfizer reported positive Phase 3 results for oral LITFULO in nonsegmental vitiligo, including meaningful facial and total-body repigmentation with a favorable safety profile. Planned regulatory submissions could broaden the drug’s use and strengthen Pfizer’s immunology pipeline. Pfizer Posted Positive Phase 3 Vitiligo Results For LITFULO
• Positive Sentiment: Pfizer declared its quarterly dividend at $0.43 per share, maintaining an annualized payout of $1.72 and a yield above 6% based on recent trading levels. The sizable income return may attract value and income-oriented investors. Pfizer Declares Fourth-Quarter 2026 Dividend
• Neutral Sentiment: Pfizer will eliminate approximately 330 jobs at its Sicily, Italy, plant. The cuts may reduce costs and align capacity with demand, but they also underscore ongoing restructuring and operational pressure. Pfizer to cut around 330 jobs in Italy
• Negative Sentiment: Vaxcyte’s VAX-31 vaccine produced competitive Phase 3 results against Pfizer’s Prevnar 20. A credible challenger could pressure Pfizer’s $6.49 billion Prevnar franchise through future pricing, market-share and revenue risks. Pfizer’s Prevnar Franchise Faces a New Challenger
• Negative Sentiment: Several valuation analyses highlight that Pfizer’s dividend payout has exceeded reported earnings, raising questions about long-term dividend sustainability despite the stock’s low valuation and high yield. This may limit upside for investors focused on earnings quality and balance-sheet strength. Is Pfizer a Good or Bad Investment at Today’s Price?

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research report on Sunday, September 13th. BMO Capital Markets reduced their price target on Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, July 13th. Cantor Fitzgerald restated a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a research note on Monday, July 6th. JPMorgan Chase & Co. dropped their price objective on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a report on Wednesday, July 8th. Finally, HSBC increased their price objective on Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a research report on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $28.56.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.